The scorecard investors already run on your commercialization plan 

Most founders assume a pitch lives or dies on the technology. The panelists on this year’s Designing for Commercialization session at Houston MedTech Oktoberfest made a different case: by the time a team is in the room, investors have usually already decided the science is credible. What they’re actually evaluating is everything sitting quietly around it that never made it onto a slide. 

The panel brought together operators and investors working across device development, including Biomerics, VISIE Inc., Contrario Medical, MedSight Capital, Forj Medical and Morgan Evans, founder of Avio Medtech Consulting. 

For early-stage medtech teams, that reframing is actually good news. It means the gap between where you are now and where an investor needs you to be is closer than it feels. 

A pitch is a systems check, not a data check 

Teams often walk into a fundraising conversation ready to defend their science. The panel’s take: investors already assume the science is real. What they’re checking for is whether the team understands how the science connects to everything else that must happen for a device to reach a patient. 

Regulatory strategy, fundraising sequencing, the design and development roadmap, clinical evidence generation, clinician adoption and the commercial and vendor strategy around a device don’t run one after another. From an investor’s perspective, they run at the same time, at every stage of a company’s life. A pitch that’s all R&D and no visibility into the other five isn’t a red flag because the R&D is weak. It’s a red flag because it leaves the connections between the pieces invisible. A team that can describe its regulatory pathway, fundraising plan, development roadmap, clinical evidence plan and commercial strategy in the same breath, instead of as five separate slides, is already answering a question most pitches never get asked: what happens after clearance? 

You don’t need a finished answer to every one of those. “We don’t know yet, here’s how we’re thinking about it” is a legitimate answer. What isn’t legitimate is not having asked the question at all. 

A pitch that only proves the technology works answers the wrong test. A pitch that shows the whole system is what actually gets funded. 

Track record beats promise, but small promises still count 

The panel’s second thread was about credibility, and it wasn’t about the size of a milestone. It was about the gap between what a team said it would do and what it actually did. 

Teams that break a roadmap into small, achievable chunks and then hit them build a different kind of trust than teams chasing one big proof point. Confirming you’ve solved a real problem, in a small and testable way, does more for an investor’s confidence than a large unproven claim, especially when that proof comes from clinicians who aren’t already advisors or friends of the company. 

That same discipline extends to how a team validates its own design before it ever reaches a pitch deck. A handful of third-party usability studies, can surface exactly the feedback that changes a device’s design while it’s still cheap to change. It’s a small line item next to the cost of a late-stage design failure discovered after the money and the runway are already spent. 

Big claims get attention. Small, delivered promises get funded. 

The common thread: plan before the pieces get expensive to move 

Every thread from the panel pointed back to timing. The teams that struggle aren’t the ones missing expertise or commitment. They’re the ones who made a decision about design, regulatory pathway, who to bring on first, before mapping how it would land on the other things happening at the same time. 

Timing is the actual mechanism here, not effort. A decision made in isolation early on can close options that are still open now, and expensive to reopen later, once capital, regulatory filings or a device’s design have already been committed. The earlier a team can see the whole system, the more room it keeps to maneuver. 

That’s why the strongest teams don’t try to avoid every mistake. They pressure-test decisions early and connect them across functions instead of treating market, regulatory, design, clinical and commercial planning as five separate workstreams to get to eventually. Those functions are interdependent from day one, not sequential stages to check off. 

Things to consider 

• Can you describe your regulatory pathway, fundraising plan, development roadmap, clinical evidence plan and commercial strategy in one breath, not five separate slides? 

• What’s the smallest version of your next milestone you could hit and prove within 90 days? 

• Have you gotten structured feedback from clinicians who aren’t already your advisors or friends of the company? 

If you’re not quite sure how to answer these questions, reach out to talk through how we can help your team navigate your next steps. 

FAQs

What do investors look for in a medtech startup’s commercialization plan? 

Investors generally want to see that a team understands how regulatory strategy, fundraising, product development, clinical evidence and commercial planning connect to each other, not just that the technology works. A plan that only addresses R&D without touching the other functions tends to raise more questions than it answers. 

Is it okay to not have all the answers when pitching to investors? 

Yes. Most experienced investors don’t expect a startup to have every question resolved, especially in early stages. What tends to matter more is showing that the team has identified the open questions and has a reasoned approach to closing them over time. 

What’s the difference between a regulatory strategy and a regulatory pathway? 

A regulatory pathway is the specific route to clearance or approval, like a 510(k) or a PMA. A regulatory strategy is the broader plan for how that pathway interacts with clinical evidence, timelines and fundraising, and how the company adapts if the pathway shifts. For more details on FDA pathways, visit our FDA pathways, simplified blog post. 

When should a medtech startup start thinking about commercialization? 

Ideally from the earliest design decisions, not after a product is built. Commercialization considerations, like clinician adoption, vendor strategy and market access, shape design and regulatory choices well before a device is ready to launch, and waiting to address them later usually means redoing work that could have been avoided.